STAAR Surgical (STAA) Hisse Özeti
STAAR Surgical Company, iştirakleri ile birlikte göz için fakik implante edilebilir lensler ve lensleri göze iletmek için aksesuar iletim sistemleri tasarlar, geliştirir, üretir ve satar. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 1/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden STAA için herhangi bir risk tespit edilmedi.
STAA Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
STAAR Surgical Company Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$27.34 |
| 52 Haftanın En Yüksek Seviyesi | US$35.87 |
| 52 Haftanın En Düşük Seviyesi | US$15.59 |
| Beta | 1.23 |
| 1 Aylık Değişim | -8.84% |
| 3 Aylık Değişim | 29.63% |
| 1 Yıllık Değişim | 64.60% |
| 3 Yıllık Değişim | -46.85% |
| 5 Yıllık Değişim | -80.85% |
| Halka arzdan bu yana değişim | 15.12% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 30
STAA: Limited China Visibility And Missing Guidance Will Constrain Future Rebound Confidence
The updated analyst price target for STAAR Surgical moves from an implied fair value of $16.00 to $23.00, reflecting adjustments to revenue growth, profit margin, and future P/E assumptions after stronger than expected Q1 results and increased confidence in a China rebound cited by several analysts. Analyst Commentary Recent Street research on STAAR Surgical has centered on stronger than expected Q1 results and growing attention on the China business, but not all commentary is uniformly bullish.Analiz Makalesi • Jun 16
STAAR Surgical (STAA) Stock Could Be 4.4% Undervalued Despite Its Rich P S Multiple
Why STAAR Surgical Stock Is Drawing Attention Now STAAR Surgical (STAA) is back on investors’ radar after a volatile period, with the stock up over the past 3 months but down over the past month and past year. See our latest analysis for STAAR Surgical. Recent trading paints a mixed picture for STAAR Surgical, with the share price at $28.37 after a 90 day share price return of 58.94%, but a 5 year total shareholder return that declined 80.85%. This suggests near term momentum in contrast with...
Anlatı Güncellemesi • Jun 16
STAA: China Rebound After Q1 Inflection Will Drive Future Re Rating
STAAR Surgical's analyst price target has been reset from $23.00 to about $39.24, with analysts pointing to stronger than expected Q1 results, signs of a China rebound, and updated long term assumptions on valuation multiples, even as management holds back on formal guidance. Analyst Commentary Recent Street research around STAAR Surgical has turned more constructive, with several bullish analysts lifting price targets and, in some cases, upgrading their ratings following the latest Q1 report.
Anlatı Güncellemesi • Jun 02
STAA: China Recovery And Profitability Improvements Will Temper Prior Bearish Reassessment
The analyst price target for STAAR Surgical has shifted from $21.11 to $29.67 as analysts factor in Q1 results that were ahead of expectations, a stronger China contribution, and slightly higher modeled profitability, even as revenue growth assumptions and the projected future P/E are revised. Analyst Commentary Recent research shows a clear shift in sentiment around STAAR Surgical, with several firms lifting price targets following Q1 results that were ahead of expectations.Recent updates
Anlatı Güncellemesi • Jun 30
STAA: Limited China Visibility And Missing Guidance Will Constrain Future Rebound Confidence
The updated analyst price target for STAAR Surgical moves from an implied fair value of $16.00 to $23.00, reflecting adjustments to revenue growth, profit margin, and future P/E assumptions after stronger than expected Q1 results and increased confidence in a China rebound cited by several analysts. Analyst Commentary Recent Street research on STAAR Surgical has centered on stronger than expected Q1 results and growing attention on the China business, but not all commentary is uniformly bullish.Analiz Makalesi • Jun 16
STAAR Surgical (STAA) Stock Could Be 4.4% Undervalued Despite Its Rich P S Multiple
Why STAAR Surgical Stock Is Drawing Attention Now STAAR Surgical (STAA) is back on investors’ radar after a volatile period, with the stock up over the past 3 months but down over the past month and past year. See our latest analysis for STAAR Surgical. Recent trading paints a mixed picture for STAAR Surgical, with the share price at $28.37 after a 90 day share price return of 58.94%, but a 5 year total shareholder return that declined 80.85%. This suggests near term momentum in contrast with...Anlatı Güncellemesi • Jun 16
STAA: China Rebound After Q1 Inflection Will Drive Future Re Rating
STAAR Surgical's analyst price target has been reset from $23.00 to about $39.24, with analysts pointing to stronger than expected Q1 results, signs of a China rebound, and updated long term assumptions on valuation multiples, even as management holds back on formal guidance. Analyst Commentary Recent Street research around STAAR Surgical has turned more constructive, with several bullish analysts lifting price targets and, in some cases, upgrading their ratings following the latest Q1 report.Anlatı Güncellemesi • Jun 02
STAA: China Recovery And Profitability Improvements Will Temper Prior Bearish Reassessment
The analyst price target for STAAR Surgical has shifted from $21.11 to $29.67 as analysts factor in Q1 results that were ahead of expectations, a stronger China contribution, and slightly higher modeled profitability, even as revenue growth assumptions and the projected future P/E are revised. Analyst Commentary Recent research shows a clear shift in sentiment around STAAR Surgical, with several firms lifting price targets following Q1 results that were ahead of expectations.Seeking Alpha • May 16
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
Summary STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China’s market rebound, normalized inventory, and rapid EVO+ ICL adoption drove topline strength, while disciplined OpEx and manufacturing efficiency boosted margins to 73.6%. STAA is benefiting from a structural shift toward lens-based refractive surgery, gaining U.S. share despite a shrinking laser market and expanding its addressable market via FDA approval. Valuation remains elevated at 4.4x forward sales and 57x forward P/E, requiring sustained high-teens revenue growth and margin expansion to justify current multiples. Read the full article on Seeking AlphaAnlatı Güncellemesi • May 15
STAA: Limited China Visibility And Missing Guidance Will Restrain Future Share Performance
Analysts have raised the fair value estimate for STAAR Surgical stock from $13.00 to $16.00, citing higher price targets supported by stronger Q1 results, improving confidence in a China rebound, and updated models that reflect better profitability assumptions and a lower future P/E multiple. Analyst Commentary Street research on STAAR Surgical has turned more constructive around the recent Q1 update, but the tone is not uniformly positive.Anlatı Güncellemesi • Apr 20
STAA: China Uncertainty And Leadership Transition Will Drive Bearish Reassessment
STAAR Surgical's updated fair value estimate shifts from $26.56 to $21.11 as analysts factor in revised Street targets. These include recent cuts to around $18 to $22 that reflect questions on China exposure and mixed near term visibility, despite some more supportive views emerging.Anlatı Güncellemesi • Apr 06
STAA: China Clarity And Post Alcon Reset Will Drive Future Re Rating
Analysts have trimmed price targets on STAAR Surgical to a range around $18 to $22, with a consensus reset of approximately $23.00, reflecting ongoing questions about China exposure, recent Q4 volatility, and limited near term visibility following the rejected Alcon deal. Analyst Commentary Recent Street commentary around STAAR Surgical centers on uncertainty, but there are pockets of optimism that readers should weigh alongside the more cautious views.Anlatı Güncellemesi • Mar 23
STAA: Ongoing China Uncertainty And Governance Turmoil Will Pressure Shares
Analysts have reduced the consolidated price target for STAAR Surgical to $22 from $28, reflecting lower assumptions for revenue growth and profit margins, a much higher future P/E multiple, and ongoing uncertainty around China and the company’s broader path forward. Analyst Commentary Recent Street research on STAAR Surgical points to a cautious tone, with multiple bearish analysts cutting price targets and reiterating neutral or underweight stances.Anlatı Güncellemesi • Mar 09
STAA: China Clarity And Post Alcon Reset Will Shape Future Upside Potential
Narrative Update on STAAR Surgical Our analyst price target for STAAR Surgical has been revised from $30.75 to $23.00 as analysts factor in recent target cuts, ongoing uncertainty around China and limited near term visibility highlighted in the latest research. Analyst Commentary Recent research on STAAR Surgical has leaned cautious, with multiple firms revising price targets lower and emphasizing uncertainty around the company’s outlook, particularly related to China and the failed Alcon transaction.Anlatı Güncellemesi • Feb 23
STAA: Post Deal Rejection Concerns Will Keep Shares Under Pressure
Analysts have reduced their average price targets on STAAR Surgical by high single digit dollar amounts to around $13.00. This reflects more cautious views on profit margins and valuation multiples after the failed Alcon deal and a series of Neutral and Underweight ratings.Anlatı Güncellemesi • Feb 08
STAA: Post Deal Collapse Uncertainty Will Pressure Shares Until Leadership Path Clears
Narrative Update on STAAR Surgical The analyst price target for STAAR Surgical has been reduced by US$8.75 following a neutral initiation, an Underweight resumption, and cautious commentary from several firms who highlight limited investor appetite until there is greater clarity on the company after the failed Alcon transaction. Analyst Commentary Recent Street research around STAAR Surgical has leaned cautious, with several firms highlighting valuation, execution, and growth risks following the failed Alcon transaction and the subsequent shareholder vote.Anlatı Güncellemesi • Jan 25
STAA: Post Alcon Deal Collapse And CEO Exit Will Cap Near Term Upside
Analysts have trimmed their fair value estimate for STAAR Surgical from US$17.41 to US$13.00, reflecting lower assumed revenue growth and a reduced future P/E multiple, alongside cautious commentary around limited buyer interest and uncertainty following the failed Alcon deal. Analyst Commentary Recent Street research has tilted clearly cautious, with several bearish analysts highlighting valuation pressure, deal uncertainty, and limited near term visibility on the business.Anlatı Güncellemesi • Jan 10
STAA: Failed Alcon Deal And Takeover Optionality Will Reshape Future Appeal
Analysts have lifted their fair value estimate for STAAR Surgical shares from US$28.00 to US$30.75, reflecting updated assumptions on growth, margins and future P/E multiples after recent debate over the failed Alcon deal and the limited near term appeal highlighted in recent research. Analyst Commentary Recent research has centered on the failed Alcon transaction, shareholder pushback on deal terms, and the limited near term appeal cited by several firms.Anlatı Güncellemesi • Dec 26
STAA: Amended Alcon Deal And Activist Push Will Drive Bullish Upside
Analysts have nudged their fair value estimate for STAAR Surgical higher from approximately $25.88 to $26.56. This reflects modestly stronger growth and margin expectations while acknowledging that any amended Alcon deal is unlikely to include a materially higher bid.Anlatı Güncellemesi • Dec 12
STAA: Merger Uncertainty Will Restrain Upside Despite Higher All-Cash Offer
Analysts have modestly raised their price target on STAAR Surgical from $16.00 to approximately $17.41 per share, citing slightly improved assumptions for long term revenue growth, profitability, and future valuation multiples, while they continue to monitor ongoing merger term discussions with Alcon. Analyst Commentary Bearish analysts highlight that the postponed shareholder meeting reinforces uncertainty around the timing and ultimate outcome of the proposed acquisition, which in turn clouds visibility on STAAR Surgical's standalone valuation.Anlatı Güncellemesi • Nov 28
STAA: Amended Merger Terms And Shareholder Opposition Will Guide Share Price Direction
Analysts have maintained their price target for STAAR Surgical at $25.88, citing limited expected upside due to ongoing merger negotiations and continued uncertainty regarding the acquisition terms. Analyst Commentary Market commentary surrounding STAAR Surgical’s ongoing merger negotiations reflects mixed analyst sentiment, with both cautious and optimistic perspectives regarding the company’s prospects and valuation.Anlatı Güncellemesi • Nov 12
STAA: Merger Discussions and Shareholder Opposition Will Shape Path Forward
Analysts have revised STAAR Surgical's price target downward to $16 from previous levels. They cite ongoing shareholder opposition to the proposed merger terms and uncertainty about a potential acquisition price.Anlatı Güncellemesi • Oct 29
Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
Analysts have raised their average price target for STAAR Surgical from $20 to $28 per share. They cite the strategic rationale and valuation of the proposed acquisition by Alcon as key drivers for the upward revision.Anlatı Güncellemesi • Oct 15
Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price target for STAAR Surgical from $24.63 to $25.88. This reflects the impact of an increased acquisition offer and the perceived strategic value from Alcon's proposed purchase.Anlatı Güncellemesi • Aug 20
Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price targets for STAAR Surgical primarily to reflect the proposed $28/share acquisition by Alcon, which sets a new benchmark valuation and limits further upside, resulting in a new consensus fair value of $24.14. Analyst Commentary Bullish analysts raised their price targets to align with the proposed $28/share acquisition price by Alcon.Anlatı Güncellemesi • Aug 06
Introduction Of EVO+ Will Open Market Opportunities In 2025
Driven by a significant improvement in net profit margin despite a higher discount rate, STAAR Surgical's consensus price target has increased from $19.20 to $22.11. What's in the News Alcon Inc.Analiz Makalesi • Jul 04
Getting In Cheap On STAAR Surgical Company (NASDAQ:STAA) Might Be Difficult
There wouldn't be many who think STAAR Surgical Company's ( NASDAQ:STAA ) price-to-sales (or "P/S") ratio of 3.2x is...Analiz Makalesi • Apr 05
Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?
Key Insights The projected fair value for STAAR Surgical is US$25.07 based on 2 Stage Free Cash Flow to Equity Current...Analiz Makalesi • Feb 14
Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge
Unfortunately for some shareholders, the STAAR Surgical Company ( NASDAQ:STAA ) share price has dived 26% in the last...Seeking Alpha • Feb 12
STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere
Summary STAAR Surgical's Q4 results were severely impacted by lower demand and high inventory levels in China. Global growth ex-China was 17% in Q4 and is expected to remain strong at 12% for FY25, with US growth of close to 15%. Cash burn is expected to be significant, but the company is financially healthy, having $232 million in cash and no debt on its balance sheet. Following the post-earnings drop, shares are cheaply valued given the long growth runway ahead, which leads me to maintain my Buy rating on STAA stock. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Summary Shares have been under pressure lately due to weak demand from China, which is by far the company’s largest market. The market opportunity in the US remains large, and management is investing heavily to tap into it. I have modest expectations for overall growth in FY25 of 9%, with markets excluding China growing significantly faster. The FCF margin in FY25 is expected to be around 8.3% given the ongoing growth investments, while I expect that it can reach close to 20% in the long term. I am assigning a Buy rating on the stock with a target priceof $35, implying an upside of over 45%. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 29
STAAR Surgical Company's (NASDAQ:STAA) Earnings Haven't Escaped The Attention Of Investors
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Analiz Makalesi • Oct 24
Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
Yeni Anlatı • Sep 13
EVO ICL Technology Transforms Vision Care, Securing Major Growth And Market Share Expansion
STAAR Surgical's record sales and expansion in the diopter curve indicate strong global adoption of EVO ICL technology and potential for increased market share.Seeking Alpha • Sep 05
STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize
Summary STAAR Surgical shares are down more than 15% since Q2 earnings, despite management raising full-year revenue guidance. Investments in the US market appear to be yielding promising results, as sales were up 25% year over year. According to my estimates, the company is on track to meet the low end of its 2026 financial targets. I have a price target of $46 by 2026, which represents an attractive upside from today’s level. Read the full article on Seeking AlphaAnaliz Makalesi • Aug 10
Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates
STAAR Surgical Company ( NASDAQ:STAA ) investors will be delighted, with the company turning in some strong numbers...Analiz Makalesi • Aug 05
STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear
When close to half the companies in the Medical Equipment industry in the United States have price-to-sales ratios (or...Analiz Makalesi • Jul 12
The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analiz Makalesi • May 27
Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?
While STAAR Surgical Company ( NASDAQ:STAA ) might not have the largest market cap around , it received a lot of...Hissedar Getirileri
| STAA | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | -6.8% | 3.1% | 0.8% |
| 1Y | 64.6% | -18.2% | 20.2% |
Getiri vs. Endüstri: STAA geçen yıl % -18.2 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: STAA geçen yıl % 20.2 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| STAA volatility | |
|---|---|
| STAA Average Weekly Movement | 9.2% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: STAA son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: STAA 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1982 | 921 | Deborah Andrews | www.staar.com |
STAAR Surgical Company, iştirakleriyle birlikte, göz için fakik implante edilebilir lensler ve lensleri göze iletmek için aksesuar iletim sistemleri tasarlar, geliştirir, üretir ve satar. Şirket, miyopi, hipermetropi, astigmatizm ve presbiyopi gibi görme bozukluklarının tedavisi için refraktif cerrahide kullanılmak üzere EVO ICL, EVO+ ICL, EVO Visian ICL ve EVO Viva ICL'den oluşan implante edilebilir kollamer lens ürün ailesi (ICL'ler) sunmaktadır. Oftalmik cerrahlar, görme ve cerrahi merkezleri, hastaneler, devlet tesisleri ve distribütörlerin yanı sıra oftalmologlar da dahil olmak üzere sağlık hizmeti sağlayıcılarına hizmet vermektedir.
STAAR Surgical Company Temel Bilgiler Özeti
| STAA temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$1.38b |
| Kazançlar(TTM) | -US$21.03m |
| Gelir(TTM) | US$290.38m |
4.7x
P/S Oranı-64.7x
F/K OranıSTAA aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| STAA gelir tablosu (TTM) | |
|---|---|
| Gelir | US$290.38m |
| Gelir Maliyeti | US$67.10m |
| Brüt Kâr | US$223.27m |
| Diğer Giderler | US$244.31m |
| Kazançlar | -US$21.03m |
Son Raporlanan Kazançlar
Apr 03, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.42 |
| Brüt Marj | 76.89% |
| Net Kâr Marjı | -7.24% |
| Borç/Özkaynak Oranı | 0% |
STAA uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/06 12:09 |
| Gün Sonu Hisse Fiyatı | 2026/07/06 00:00 |
| Kazançlar | 2026/04/03 |
| Yıllık Kazançlar | 2026/01/02 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
STAAR Surgical Company 20 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Gorman | BTIG |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |